Advertisement

Interferonrezeptoren maligner Tumoren und ihre mögliche Bedeutung für die Interferontherapie

  • H. H. Bartsch
  • K. Pfizenmaier
  • U. Ücer
  • G. A. Nagel
Conference paper

Zusammenfassung

Durch Einführung der recombinanten DNA-Technologie ist es möglich geworden, α-, ß- und γ-Interferone standardisiert in ausreichender Menge herzustellen. Mit Hilfe dieser hochgereinigten Proteine (> 98% Reinheit) ist es erstmals möglich geworden, die in vitro erhobenen Befunde der antiviralen sowie antitumoralen Eigenschaften von Interferon in größeren klinischen Studien zu überprüfen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allen G, Fante KH (1980) A family of structural genes for human lymphoblastoid (leucocyte type) interferon. Nature 287:408–411PubMedCrossRefGoogle Scholar
  2. 2.
    Ahström L, Dohlwitz A, Strander H, Carlström G, Cantell K (1974) Interferon in acute leucemia in children. Lancet 166–167Google Scholar
  3. 3.
    Ameglio F, Capobianci MR, Dolei A, Tosi R (1983) Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC Loci. Infection and Immunity 42:122–125PubMedGoogle Scholar
  4. 4.
    Anderson P, Yip YK, Vilcek J (1982) Specific binding of 125J-human interferon-gamma to high affinity receptors on human fibroblasts. J Biol Chem 257:11301–11304PubMedGoogle Scholar
  5. 5.
    Bartsch H-H, Schuff-Werner P, Schreml W, Nagel GA, Seeber S, Queißer W, Freund M (1984) Recombinant alpha-leukocyte interferon for the treatment of patients with soft tissue sarcomas. Cancer Res Clin Oncol 107:3Google Scholar
  6. 6.
    Balkwille FR (1979) Interferons as cell-regulatory molecules. Cancer Immunol Immunother 7:7–14Google Scholar
  7. 7.
    Balkwille FR, Modie EM, Fredman V, Fantes KH (1982) Human interferon inhibits the growth of established human breast tumors in the nude mouse. Int J Cancer 30:231–235CrossRefGoogle Scholar
  8. 8.
    Basham TY, Bourgeade MF, Creasey AA, Merigan TC (1982) Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and sensitive cell Unes. Proc Natl Acad Sci 79:3265–3269PubMedCrossRefGoogle Scholar
  9. 9.
    Bekesi JG, Roboz JP, Zimmermann E, Holland JF (1976) Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy or interferon. Cancer Res 36:631–639PubMedGoogle Scholar
  10. 10.
    Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang YC, Datei J (1982) Leukocyte-derived interferon (alpha) in human breast carcinoma. Ann Int Med 97:1–6PubMedGoogle Scholar
  11. 11.
    Chapekar MS, Glazer RI (1984) Effects of human immune interferon on cell viability, (2’,5’) ligo adenylate synthesis and polyamine-dependent protein phosphorylation in human colon carcinoma cells in vitro. Cancer Res 44:2144–2149PubMedGoogle Scholar
  12. 12.
    Foon KA, Sherwin SH, Abrams PG (1984) Treatment of advanced non-Hodgkin’s lymphoma with recombinant leucocyte A interferon. N Engl J Med 311:1148–1152PubMedCrossRefGoogle Scholar
  13. 13.
    Gastl G, Denz H, Abbrederis C, Huber H, Proppmair J, Wiegele J, Niederwieser D, Flener R, Huber C (1985) Treatment with low dose human recombinant interferon alpha-2 ARG induces complete remission in patients with hairy cell leukemia. Onkologie 8:143–144PubMedCrossRefGoogle Scholar
  14. 14.
    Giacomini P, Agerzzi A, Pstka S, Fischer PB, Ferrone S (1984) Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA and tumor associated antigens by human melanoma cells. J Immunol 133:1649–1655PubMedGoogle Scholar
  15. 15.
    Groopman JE, Gottlieb MS, Goodman J (1984) Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrom. Ann Intern Med 100:671-676PubMedGoogle Scholar
  16. 16.
    Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z (1982) Recombinant leucocyte A interferon: pharmacokinetics, singlebone tolerance and biologic effects in cancer patients. Ann Int Med 96:549–556PubMedGoogle Scholar
  17. 17.
    Kirchner H (1984) Interferon gamma. Progress in Clin Biochem Med I:169–203Google Scholar
  18. 18.
    Kirkwood JM, Ernstoff MS (1984) Interferons in the treatment of human cancer. J Clin Oncol 2:336–352PubMedGoogle Scholar
  19. 19.
    Koeffler HD, Ranyard J, Yelton L, Billing R, Bohmann R (1984) Gamma-interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells. Proc Natl Acad Sci 81:4080–4084PubMedCrossRefGoogle Scholar
  20. 20.
    Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU (1985) Pharmacokinetics, single dose tolerance and biological activity of recombinant gammainterferon in cancer patients. Cancer Res 45:2866–2872PubMedGoogle Scholar
  21. 21.
    Leavitt RD, Kaplan S, Bonnem E, Grimm M, Ozer H, Portlock C, Ratanathanathorn V, Karanes C, Ultmann J, Rudnick S (1985) High and low dose treatment for high and low grade non-Hodgkin’s lymphoma. In: Kisner DL, Smyth JF (eds) Interferen alpha-2: pre-clinical and clinical evaluation. Martinus Nijhoff Publishers, Boston Dorchredt LancesterGoogle Scholar
  22. 22.
    Littmann SJ, Faltyrek CR, Baglioni C (1985) Binding of human recombinant 125J-interferon to receptors on human cells. J Biol Chem 260:1191–1195Google Scholar
  23. 23.
    Lotzová E, Savary CA, Guttermann JU, Hersh EM (1982) Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 42:2480–2488PubMedGoogle Scholar
  24. 24.
    Mahmoud HK, Öhl S, Schäfer UW, Beelen D, Grosse-Wilde H, Doxiadis I, Richter HJ, Schmidt CG (1985) Behandlung der Haarzell-Leukämie mit rekombinantem Leukozyten A-Interferon. Onkologie 8:141–142PubMedCrossRefGoogle Scholar
  25. 25.
    Mitsuyasu R, Volberding P, Jacobs A (1984) High dose alpha-2 recombinant interferon (IFN) in the therapy of epidemic Kaposi’s sarcoma (KS) in acquired immune deficiency (AIDS). Proc Am Soc Oncol 3:51Google Scholar
  26. 26.
    Muss HB, Kempf RA, Martino S (1984) A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J Clin Oncol 2:1012–1016PubMedGoogle Scholar
  27. 27.
    Nagata S, Taira H, Hall A, Johsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E.coli of a polypeptide with human leukocyte interferon activity. Nature 284:316–320PubMedCrossRefGoogle Scholar
  28. 28.
    Nethersell A, Smedly H, Katrak M (1984) Recombinant interferon in advanced breast cancer. Brit J Cancer 49:615–620PubMedCrossRefGoogle Scholar
  29. 29.
    Padmanabhan N, Balkwill FR, Bodmer J (1984) Recombinant DNA human interferon alpha 2 in advanced breast cancer. Proc Am Assoc Cancer Res 25:170Google Scholar
  30. 30.
    Pfizenmaier K, Bartsch H, Scheurich P, Seliger B, Ücer U, Vehmeyer K, Nagel GA (1985) Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effecs of gamma-interferon on tumor cell growth. Cancer Res 45:3503–3509PubMedGoogle Scholar
  31. 31.
    Quesada JR, Hawkins M, Horning S (1984a) Collaborative phase I—II study of recombinant DNA produced leucocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Ann J Med 77:427–432CrossRefGoogle Scholar
  32. 32.
    Real FY, Krown SE, Krim M (1984) Treatment of Kaposi’s sarcoma (KS) with recombinant leucocyte A interferon (rIFN-alpha A). Proc Am Soc Clin Oncol 3:55Google Scholar
  33. 33.
    Rosa R, Hatat D, Abachie A, Fellous M (1985) Regulation of histocompatibility antigens by interferon. Ann Inst Pasteur/Immunol 136:103–119CrossRefGoogle Scholar
  34. 34.
    Sherwin SA, Knost JA, Fein S (1982) A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:1461–2466CrossRefGoogle Scholar
  35. 35.
    Sherwin SA, Foon KA, Abrams PG, Heyman MR, Ochs JJ, Watson T, Maluish A, Oldham RK (1984) A preliminary phase I trial of partially purified interferon-gamma in patients with cancer. J Biol Resp Modifiers 3:599–607Google Scholar
  36. 36.
    Silgas RM, Ahlgren JD, Neefe JR, Rothmann J, Rudnick S, Galicky P, Schein P (1984) A phase II-trial of high dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54:2257–2261CrossRefGoogle Scholar
  37. 37.
    Ücer U, Bartsch H, Scheurich P, Pfizenmaier K (1985) The biological effects of gamma-interferon on human tumor cells: the quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression. Int J Cancer 36:103–108PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • H. H. Bartsch
  • K. Pfizenmaier
  • U. Ücer
  • G. A. Nagel

There are no affiliations available

Personalised recommendations